Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in hemodialysis (HD) patients. Hypertension (HT) is a major risk factor for CVD. The renin-angiotensin-aldosterone system (RAAS) plays pivotal roles in the pathogenesis of HT in HD patients. Previous studies suggested that the blockade of RAAS may be effective to control blood pressure (BP) and to prevent CVD in HD patients. A certain level of preventive effects against CVD by RAAS blockade in HD patients has been reported independently from a BP lowering effect. This review focuses on the effect of blocking RAAS in HD patients for the control of HT and the prevention of CVD
Keywords: Hemodialysis patinets, renin, angiotensin I, angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, direct renin inhibitor, angiotensin-receptor blocker, blood pressure, cardiovascular disease
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: The Blockade of Renin-Angiotensin-Aldosterone System in Hemodialysis Patients to Control Hypertension and Prevent Cardiovascular Disease: Optimal Pharmacotherapy
Volume: 9 Issue: 4
Author(s): Yoshiyuki Morishita and Eiji Kusano
Affiliation:
Keywords: Hemodialysis patinets, renin, angiotensin I, angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, direct renin inhibitor, angiotensin-receptor blocker, blood pressure, cardiovascular disease
Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in hemodialysis (HD) patients. Hypertension (HT) is a major risk factor for CVD. The renin-angiotensin-aldosterone system (RAAS) plays pivotal roles in the pathogenesis of HT in HD patients. Previous studies suggested that the blockade of RAAS may be effective to control blood pressure (BP) and to prevent CVD in HD patients. A certain level of preventive effects against CVD by RAAS blockade in HD patients has been reported independently from a BP lowering effect. This review focuses on the effect of blocking RAAS in HD patients for the control of HT and the prevention of CVD
Export Options
About this article
Cite this article as:
Morishita Yoshiyuki and Kusano Eiji, The Blockade of Renin-Angiotensin-Aldosterone System in Hemodialysis Patients to Control Hypertension and Prevent Cardiovascular Disease: Optimal Pharmacotherapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (4) . https://dx.doi.org/10.2174/187152511798120903
DOI https://dx.doi.org/10.2174/187152511798120903 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Network Building of Proteins in a Biochemical Pathway: A Computational Biology Related Model for Target Discovery and Drug-Design
Current Bioinformatics Outcomes of Clinical Treatments Among Patients with Diabetes Mellitus in Selangor, Malaysia: A Retrospective Study
Current Diabetes Reviews Neuronal Nitric Oxide Synthase and Sympathetic Nerve Activity in Neurovascular and Metabolic Systems
Current Neurovascular Research Does Brachial Blood Pressure Need to Predict Cardiovascular Outcomes in End Stage Renal Disease? An Update
Current Hypertension Reviews Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The-N-End Rule: The Beginning Determines the End
Protein & Peptide Letters The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Rational Drug Design Paradigms: The Odyssey for Designing Better Drugs
Combinatorial Chemistry & High Throughput Screening Benefits of Resistance Training in Older Adults
Current Aging Science Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Angiotensin II in Type 2 Diabetes Mellitus
Current Protein & Peptide Science Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets
Current Drug Metabolism Antenatal Hypoxia and Pulmonary Vascular Function and Remodeling
Current Vascular Pharmacology Optimizing the Management of Uncontrolled/Resistant Hypertension. The Importance of Sleep Apnoea Syndrome
Current Vascular Pharmacology Anatomy, Physiology and Pathophysiology of Haemorrhoids
Reviews on Recent Clinical Trials Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry